Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$4.46 - $6.68 $3.12 Million - $4.68 Million
-700,000 Reduced 35.9%
1,250,000 $6 Million
Q2 2020

Aug 14, 2020

BUY
$4.69 - $7.81 $351,750 - $585,750
75,000 Added 4.0%
1,950,000 $12.5 Million
Q1 2020

May 15, 2020

BUY
$5.5 - $12.3 $10.3 Million - $23.1 Million
1,875,000 New
1,875,000 $10.8 Million

Others Institutions Holding CFRX

About CONTRAFECT Corp


  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.